BI Asset Management Fondsmaeglerselskab A S Cuts Position in Halozyme Therapeutics, Inc. $HALO

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

BI Asset Management Fondsmaeglerselskab A S cut its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 12.6% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 373,492 shares of the biopharmaceutical company's stock after selling 53,715 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S owned approximately 0.30% of Halozyme Therapeutics worth $23,833,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Fuller & Thaler Asset Management Inc. lifted its position in Halozyme Therapeutics by 27.3% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,130,019 shares of the biopharmaceutical company's stock valued at $72,107,000 after acquiring an additional 242,167 shares during the last quarter. Quantbot Technologies LP increased its position in shares of Halozyme Therapeutics by 16.1% during the first quarter. Quantbot Technologies LP now owns 8,891 shares of the biopharmaceutical company's stock worth $567,000 after purchasing an additional 1,230 shares in the last quarter. Brooklyn Investment Group boosted its position in shares of Halozyme Therapeutics by 1,558.1% in the 1st quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 670 shares in the last quarter. Nations Financial Group Inc. IA ADV boosted its position in shares of Halozyme Therapeutics by 2.6% in the 1st quarter. Nations Financial Group Inc. IA ADV now owns 14,429 shares of the biopharmaceutical company's stock worth $921,000 after purchasing an additional 367 shares in the last quarter. Finally, American Century Companies Inc. grew its stake in Halozyme Therapeutics by 3.4% during the 1st quarter. American Century Companies Inc. now owns 895,412 shares of the biopharmaceutical company's stock worth $57,136,000 after buying an additional 29,046 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Insider Buying and Selling

In other news, CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $63.51, for a total transaction of $1,270,200.00. Following the sale, the chief executive officer owned 733,719 shares of the company's stock, valued at $46,598,493.69. This trade represents a 2.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last 90 days, insiders sold 80,000 shares of company stock valued at $4,532,600. Corporate insiders own 2.40% of the company's stock.

Halozyme Therapeutics Stock Performance

NASDAQ HALO traded up $0.48 on Thursday, reaching $71.61. 1,863,714 shares of the company's stock traded hands, compared to its average volume of 2,029,159. Halozyme Therapeutics, Inc. has a fifty-two week low of $42.01 and a fifty-two week high of $72.33. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36. The firm has a market cap of $8.38 billion, a price-to-earnings ratio of 16.39, a P/E/G ratio of 0.40 and a beta of 1.17. The stock has a 50 day moving average price of $58.36 and a 200-day moving average price of $58.64.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, beating analysts' consensus estimates of $1.23 by $0.31. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The business had revenue of $325.72 million during the quarter, compared to analyst estimates of $282.66 million. During the same quarter last year, the business posted $0.91 EPS. The company's revenue was up 40.8% on a year-over-year basis. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Equities research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on HALO shares. Wells Fargo & Company raised their price target on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a report on Wednesday, May 7th. JMP Securities boosted their target price on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a "market outperform" rating in a research report on Wednesday, August 6th. Leerink Partners cut shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target for the company. in a report on Tuesday, May 13th. The Goldman Sachs Group initiated coverage on shares of Halozyme Therapeutics in a research note on Thursday, July 10th. They set a "neutral" rating and a $55.00 price objective for the company. Finally, HC Wainwright upped their target price on Halozyme Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research report on Wednesday, August 6th. Four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $67.11.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.